Background-We have reported that N-(phosphonacetyl)-Laspartic acid (PALA) 1266 mg/m 2 can safely be given 24 hours prior to the start of a 72-hour infusion of fluorouracil (FUra) and leucovorin (LV) at doses of 2000 and 500 mg/m 2 /day Since inhibition of aspartate carbamoyltransferase (ACTase) activity was evident 4 hours post PALA, we wished to evaluate PALA given 1 hour prior to FUra Further, we studied the toxicity and pharmacokinetics with FUra given by either fixedor variable-rate infusion
Introduction
Preclinical and clinical studies have shown improved anticancer activity with the combination of fluorouracil (FUra) and calcium leucovorin (LV) compared to FUra alone by virtue of greater inhibition of thymidylate synthase (EC 2.1.1.45, TS) [1] . N-(phosphonacetyl)-Laspartate (PALA) is a transition state inhibitor of aspartate carbamoyltransferase (EC 2 1 3.2, ACTase), which carries out the second step in de novo pynmidine synthesis. ACTase inhibition leads to a reduction in the endogenous cytidine and uridine ribonucleotide and deoxyribonucleotide pools, thus interfering with both RNA and DNA synthesis [2] . A number of preclinical studies demonstrated enhanced cytotoxicity with the combination of PALA/FUra compared to FUra alone The basis for this potentiation was PALA-mediated decreases in competing pools of endogenous nucleotides such as UTP and dUMP, which interfere with FUTP-RNA incorporation and inhibition of TS by 5-fluoro-2'-deoxyundine monophosphate (FdUMP), respectively.
The addition of PALA to LV-modulated FUra is theoretically appealing. Because FUra has a very short plasma half-life, continuous infusional schedules allow sustained FUra plasma exposure As the duration of infusion increases, the probability that a given tumor cell will enter the synthetic phase of the cell cycle during drug exposure also increases. Preclinical studies confirm a schedule-dependent cytotoxicity of FUra, with better antitumor effects when the duration of exposure exceeds 24 hours [3, 4] . Preclinical studies also suggest that continuous exposure to LV for 24 hours or longer favors the formation of intracellular reduced folate polyglutamates, which have prolonged intracellular retention and a greater capacity to participate in ternary complex formation compared to the monoglutamate forms [5] [6] [7] .
We tested the feasibility of combining these three agents in a clinical study which showed that PALA doses at or below 1266 mg/m 2 could safely be given 24 hours prior to the start of a 72-hour infusion of combined FUra 2000 mg/m 2 /day and high-dose LV at 500 mg/m 2 /day [8] . Biochemical monitoring with this regi-* The US Government's right to retain a non-exclusive, roydlty-free licence in and to any copyright is acknowledged men revealed a modest decrease in plasma uridine levels even at the lowest PALA dose tested, 250 mg/m 2 . Since previous studies have shown that the liver plays a pivotal role in regulating the concentration of circulating undine, the PALA-mediated decreases in plasma undine may primarily reflect inhibition of ACTase activity in hepatic tissue [9, 10] In contrast, using a novel assay that measured ACTase activity in cellular lysates from peripheral blood mononuclear cells (PBMCs), we found that PALA at or below 844 mg/m 2 did not appreciably inhibit enzyme activity at 24 hours [8] More pronounced inhibition of enzyme activity in PBMCs was evident 24 hours after PALA ^ 1266 mg/m 2 . Of additional importance, the delivered FUra dose intensity for patients entered at or above 1750 mg/m 2 per day was not compromised by the addition of PALA. Since PALA 1266 mg/m 2 was biochemically active and well tolerated with infusional FLJra/LV, it was recommended for future studies [8] Because ACTase was not uniformly inhibited at 24 hours with 1266 mg/m 2 of PALA, however, we determined whether inhibition was greater at an earlier time point in a cohort of seven patients [8] . Inhibition of ACTase activity was evident 4 hours post PALA, suggesting that the conventional 24-hour interval between PALA and the start of the FUra infusion might not be optimal. We therefore designed a new trial to evaluate the clinical toxicity associated with 1266 mg/m 2 PALA given one hour prior to the start of the FUra/LV infusion Because this modification could potentially result in greater host toxicity, the starting dose of FUra used in this trial was reduced from 2000 to 1750 mg/m 2 /day. Levi and colleagues have reported that administering FUra over 11.5 hours daily for five days with a sinusoidal pattern to achieve peak delivery at 4:00 AM IS associated with an improved therapeutic index compared to infusion of FUra at a constant rate over 24 hours daily [11, 12] We therefore compared a similar chronomodulated infusion profile with peak delivery at 4 00 A M to a constant-rate infusion in the same patients using a programmable infusion pump. Finally, the effect of PALA administration on ATCase activity in PBMC at different intervals was examined In the initial part of this study, all patients received PALA 1266 mg/m 2 over 15 min, followed by a loading dose of LV 500 mg/m 2 intravenously over 30 min, then a 72-hour concurrent continuous intravenous infusion of LV 500 mg/m 2 /day mixed with FUra 1750 mg/m 2 / day using a fixed-rate of infusion such that 4 2% of the total daily doses of LV/FUra was given per hour Hepann 10 U/ml was added to the infusion solution Patients were instructed to flush their central access lines every eight hours during the FUra/LV infusion to prevent possible catheter blockage caused by drug precipitation For the first cohort of patients, the intention was to administer two consecutive cycles using a constant rate of FUra/LV infusion to permit pharmacokinetic sampling at three-hour intervals during hours 24-48 of two sequential cycles in which the same dose of FUra was administered
Patients and methods

Materials
The subsequent cycle, the same doses of FUra/LV and PALA were to be administered, but the rate of FUra infusion was to be varied in a arcadian pattern using an Intelliject™ four-channel pump (Ivion Corporation, Englewood, Colorado) Three of the channels contained FUra, while the fourth channel contained LV The rate of infusion for the channels containing FUra were programmed such that 85% of the total daily dose would be administered between 10 00 PM and 10 00 A M , with the peak infusion rate at 4 00 A M ( Figure 1 ) The rate of LV administration remained constant The protocol was subsequently amended to allow administration of the arcadian rate of infusion starting cycle I for the final five patients Cycles were repeated every 21 days provided that the absolute granulocyte count (AGC) had recovered to ^1500/ul, the platelet count was > 80,000/ul, and non-hematologic toxicity had resolved The daily FUra dose was reduced 15% for grade 3 or worse nonhematologic toxicity, a granulocyte nadir < 500/ul, or a platelet nadir <25,000/ul The dose of LV was not modified Individual patients were allowed to receive a 15% escalation of FUra in the subsequent cycle provided that the AGC nadir was > 1200/ul. the platelet nadir waŝ 60,000/ul, and non-hematologic toxicity was ^ grade I in seventy Patients were continued on therapy until disease progression Standard response criteria were used Time to treatment failure was computed actuanally using the Kaplan-Meier method beginning with the on-study date and finishing with the date patients were removed from therapy [13] Pharmacokinetic analysis Blood sampling began on the second day of the constant rate or arcadian infusion of FUra, samples were obtained every 3 hours for 24 hours at a similar time of day for all patients Venous blood samples were collected in hepannized tubes, placed on ice immediately and centrifuged at 800 x g at 4°C for 10 min The plasma was then Figure 1 Program pattern for variable-rate 5-fluorouracil infusion separated and frozen at -70 °C for later analysis Plasma was spiked with a fixed amount of the internal standard (5-chlorouracil), then were extracted with 8 ml ethyl acetale-methanol (95% 5%, v/v) The supernatant was concentrated to dryness, resuspended in 500 ul water, and analyzed by reversed-phase high performance liquid chromatography as previously described [14] The ratio of FUra to the internal standard in the patient samples was used to determine the FUra plasma concentrations by comparison with a standard curve of FUra and internal standard prepared using donor plasma The data were analyzed by a non-compartmental model with WinNonLin™ software, version 3 1 (Pharsight Corporation, Mountain View, California) For the variable-rate infusion cycles, plasma concentrations that were below detection were specified as 0 I uM (one-half the limit of quantitation), rather than zero, in order to include these data points in the calculation of area under the concentration-time curve (AUC) The AUC was calculated by the linear trapezoidal rule, and the clearance was estimated by dividing the daily FUra dose in mg by the AUC
Effects of PALA on ACTase activity in peripheral blood mononuclear cells
Heparimzed peripheral blood samples were obtained prior to, and 4, 24 and 72 hours after PALA administration Peripheral blood mononuclear cells (PBMCs) were isolated using differential centrifugation in Lymphocyte Separation Medium™ (Organon Teknika, Durham. North Carolina) following the manufacturer's guidelines An aliquot of the PBMCs was counted by hemacytometer, and the remaining cell pellet was stored at -70 °C until analysis ACTase activity was measured by the conversion of [ l4 C]carbamoyl phosphate to [ l4 C]carbamoyl aspartate in the presence of excess cold aspartate Parent and product compounds were resolved and quantified by anion-exchange high performance liquid chromatography with in-line scintillation detection as previously described [15] Enzyme activity was expressed as pmol metabolites formed per min per million nucleated cells
Results
Patient characteristics
Twenty-seven patients were entered into this study ( sequently received at least one cycle with a sinusoidal infusion pattern of FUra at the same dose. Five patients received a arcadian infusion of FUra at 1750 mg/m 2 / day over three days during their initial cycle, and three of these patients were given a constant rate infusion later in their treatment course. Therefore, a total of 25 patients received one or more constant-rate infusion cycles, 20 patients received one or more variable-rate infusion cycles, of whom 19 were evaluable for toxicity (one patient refused further follow-up after receiving the 72-hour infusion)
Toxicity
During the first cycle, no instance of grade 4 toxicity occurred Three of twenty-two patients receiving fixed-(14%) and one of five patients (20%) receiving the variable-rate infusion experienced grade 3 stomatitis. The incidence of grade 2 or worse mucositis was 2 7-fold higher in patients receiving the constant rate infusion (54% vs. 20%), but the difference in the proportions was not significant due to the small number of patients receiving the variable-rate infusion during cycle one
Comparison of clinical toxicity in two consecutive cycles in which a fixed-rate and variable-rate infusion were given at the same dose of FUra was possible in 17 patients. No significant differences were noted in the incidence of toxicities in the matched cycles: grade 2 nausea/vomiting, 23.5% vs 17 6%, grade 2 stomatitis, 41.2% and 35 3%; grade 2 diarrhea, 23.5% vs. 17 6%. The worst toxicity experienced by each patient while receiving either a constant-or variable-rate infusion is presented in Table 2 . The most common toxicity was stomatitis, which was dose-limiting in 12% and 16% of patients receiving constant-rate and sinusoidal infusions, respectively Both generalized body rashes and hand-foot syndrome were seen, but were rarely dose-limiting. 
Clinical activity
Three patients did not have measurable disease Six of the remaining twenty-four patients had a partial response (25%), including three of five patients with colorectal cancer, one of three patients with gastric cancer, and two of sixteen patients with pancreatic cancer. Seven other patients (29%) had stable disease for three months or longer. The median progression-free survival (PFS) for all patients was 2.9 months. One patient with colon cancer with surgically documented intra-abdominal disease requested to be taken off study after nine months for treatment-related toxicity (recurrent episodes of abdominal pain). The episodes of abdominal pain ceased when therapy was discontinued, and he had no clinical evidence of disease progression for 5.5 years. For the 18 patients with pancreatic cancer, the median PFS was only 2.0 months, but four patients (22%) remained progression-free for longer than one year.
FUra pharmacokinetics
We have previously reported an analysis of the inter-and intra-patient variation in FUra plasma concentrations (Cp) in a subset of these patients receiving a fixed-rate FUra infusion [16] . The present analysis includes data from all patient cycles in which four to nine plasma samples were taken throughout the second day of FUra infusion. FUra Cp versus time from 16 patients (29 cycles) are shown in the top panel of Figure 2 , and the parameters are summarized in Table 3 . With fixed-rate FUra infusion, the average ratio of the maximum to minimum Cp value for a given cycle was 2.0 No correlation was evident between the average FUra plasma concentrations and the severity of stomatitis and diarrhea, which is most likely due to the limited occurrence of severe stomatitis and diarrhea (7% and 0% of 29 fixed cycles with pharmacokinetic analysis, respectively)
A circadian profile was imposed by the programmed variable-rate infusion as expected, the trough occurred between 2 PM and 5 PM, while the peak occurred 12 hours later (Figure 2 , bottom pannel). Six patients had FUra plasma levels below the limits of detection for the five PM sample. The median of the maximum values was about 18-fold higher than that of the minimum detectable values. In nine patients who received paired cycles of fixed-and variable-rate at the same dosage of FUra, the average FUra Cp and AUC were similar (data not shown). The results suggest that although striking differences were evident in the profile of FUra Cp over the 24-hour sampling period, the total FUra exposure was similar
PALA-mediated inhibition of ACTase activity
Paired pre-PALA and post-treatment PBMC samples were available from 20 patients (Figure 3 ). Baseline ACTase activity was 72.6 ± 54.5 pmol/min/milhon cells (mean ± SD). ACTase activity was significantly decreased at both 4 and 24 hours after PA LA administration (12% and 18% of baseline, respectively; P < 0.001, Wilcoxon rank-sum test). Enzyme activity had recovered to 40% of the pre-treatment values by 72 hours post PA LA in three patients. recommendation of PALA 250 mg/m 2 as a biochemically active dose stemmed from a clinical trial using an indirect assay that evaluated effects of PALA on pyrazofunn-mediated changes in plasma and urinary levels of orotate and orotidine [19] . The most popular regimen using low-dose PALA, developed by Ardalan et al., involved weekly administration of PALA 250 mg/m 2 followed 24 hours later by a 24-hour infusion of FUra [20] . A subsequent phase II trial in metastatic colorectal carcinoma confirmed that this was an active and welltolerated regimen [21] . However, two randomized clinical trials that compared a weekly 24-hour infusion of FUra alone or with low-dose PALA 250 mg/m 2 given 24 hours prior have failed to demonstrate a benefit for PALA modulation [22, 23] Our prior trial demonstrated that, depending on the surrogate marker used to assess the biochemical efiects of PALA, different conclusions could be drawn. Based on decreases in plasma uridine, 250 mg/m 2 PALA had The dose of FUra was 1750 mg/m in all but two cycles of the fixed-rate and one cycle of the variable-rate, in which case the dose was 2000 mg/m 2 The samples were drawn throughout the second day of FUra infusion, and the data were analyzed by non-compartmental analysis The AUC was determined by the trapezoidal method, and the clearance was calculated by dividing AUC by the total FUra dose a similar biochemical effect as higher PALA doses However, substantial inhibition of ACTase activity in PBMCs required PALA doses of 1266 mg/m 2 or higher Further, time-course studies suggested that ACTase inhibition was strongly inhibited four hours after PALA, questioning the need for a 24-hour delay between PALA and FUra Fleming et al. studied ACTase activity in peripheral white blood cells in patients receiving PALA day I with bolus 5-FU 400 mg/m 2 given days 2-5, and found that ACTase activity was inhibited in a dosedependent manner [24] . PALA doses of 125, 250, 500, and 1000 mg/m 2 resulted in an average of 0%, 13%, 17%, and 49% inhibition across days 2-5 following each PALA dose The higher dose of PALA needed to substantially inhibit ACTase activity in mononuclear and white blood cells compared to the lower doses identified with indirect assays is most likely explained by different enzyme activities in various host tissues.
Based on this information, we wished to evaluate the potential impact of 1266 mg/m" PALA given 1 hour prior to the institution of a 72-hour infusion of FUra/ LV given every 3 weeks. To minimize the risk of clinical toxicity, the starting dose of FUra was lowered from 2000 to 1750 mg/m 2 /day of FUra We found that ACTase activity was significantly inhibited at 4 and 24 hours post PALA, confirming the results of our prior study A number of clinical studies have indicated that administration of FUra or fluorodeoxyundine using a sinusoidal infusion profile is better tolerated compared to a constant-rate infusion [11, 12, 25, 26] . A regimen developed by Levi and colleagues involves administration of 5-FU/LV (600 & 300 mg/m 2 /day) between 10:15 PM and 9 45 A M , with peak delivery at 4.00 A M , and oxahplatin (20 mg/m 2 /day) given between 10.15 A M to 945 PM with a peak at 400 PM , repeated daily for five days every three weeks. Other investigators have recommended a variable-rate schedule in which twothirds of the total daily dose of 5-FU is given during the evening hours [27] A question is whether the reduction in clinical toxicity with these chronomodulated infusion programs is related to intermittent drug exposure rather than to the specific timing of peak drug infusion. To address this issue, Falcone and coworkers conducted a study in which 113 patients were randomized to receive either a constant rate infusion of FUra/LV (200 and 5 mg/m 2 daily for 14 days) or one of three chronomodulated regimens in which two-thirds of the total daily dose was given over eight hours from either 0-8 hours, 8-16 hours, or 16-24 hours, while the remaining onethird of the dose was given over the remaining 16 hours. During the initial cycle of therapy, the incidence of diarrhea and stomatitis was significantly higher with the constant-rate infusion compared to the three chronomodulated regimens. Over all cycles, a significant increase in the 5-FU dose intensity was evident for each of the chronomodulated regimens compared to the constantrate schedule, but this did not translate into an improved response rate. These results indicate that a reduction in toxicity and increase in dose intensity was achieved with a non-sinusoidally chronomodulated infusion, but the effect depended mainly on intermittent FUra exposure each day as opposed to the specific timing of drug delivery We also observed that the FUra dose-intensity was somewhat higher with the variable-rate infusion in the present study. No appreciable differences in toxicity were noted, but this may have been due to the sample size, and the low incidence of serious toxicities with the fixed-rate infusion.
In summary, this regimen of PALA and LV-modulated FUra was active and well tolerated with either fixed-or variable rate FUra infusion. The pharmacokinetic data confirm that a circadian profile of FUra Cp can be imposed with a programmable infusion pump. Although the FUra Cp profiles over a 24-hour period were strikingly different with the constant-and variablerate infusions, the average Cp and AUC were similar. PALA 1266 mg/m 2 significantly inhibited ACTase activity for at least 24 hours oxahplatin, fluorouracil, and folinic acid (leucovonn) in palienls
